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What is New in the NARMS Report for 2009 
Mutually exclusive c riteria heading 
In Box 2 (page 47), we describe the 4 most common multidrug-resistant (MDR) patterns among non-typhoidal 
Salmonella isolates based on resistance to 7 of the 15 agents currently tested in NARMS: ampicillin (A), 
chloramphenicol (C), streptomycin (8), sulfonamide (Su), tetracycline (T), amoxicillin-clavulan ic acid (Au), and 
ceftriaxone (ex) . Resistance to the 7 agents has been used in NARMS to categorize specific MDR patterns. 
Unlike MDR criteria used for tables in previous reports and other sections of this report, we used mutually 
exclusive criteria in the new section. Use of mutually exclusive criteria is important in mon itoring major and 
emerging patterns, which may be driven by different resistance mechanisms. 
Update of trimethoprim-sulfamethoxazole data for Shigella 
Automated fluorescence-based methods have been used since 2001 to determine minimum inhibitory 
concentrations (MIG) for the drugs tested for Enterobacteriaceae. These automated fluorescence-based methods 
are designed to emulate MIGs that wou ld be obtained if the results were read visually. Recent laboratory 
comparison studies showed that the automated fluorescence-based method was not reproducibly emulating 
visually-determined results for trimethoprim-su lfamethoxazole with Shigella species. The test manufacturer has 
updated the automated fluorescence-based method to improve concordance with visual results, and these 
updates have been applied retroactively to the affected data in the database. This has resulted in lower MIG 




The National Antimicrob ial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among 
the Centers for Disease Control and Prevention (CDC). U.S. Food and Drug Administration's Center for 
Veterinary Medicine (FDA-CVM), and U.S. Department of Agriculture (USDA). The primary purpose of NARMS at 
CDC is to monitor antimicrobial resistance among enteric bacteria isolated from humans. Other components of 
the interagency NARMS program include surveillance for resistance in enteric bacteria isolated f rom foods, 
conducted by the FDA-CVM 
(http://w'ww.fda.qov/AnimaIVeterinarvISafetvHealth/AnlimicrobialResistance/NationalAntimicrobialResistanceMoni 
toringSystemldefault.htm), and resistance in enteric bacteria isolated from animals, conducted by the USDA 
Agricultura l Research Service (http:/twww.ars.usda.gov/main/site main.htm?modecode=66-12-05-08). 
Many NARMS activities are conducted within the framework of CDC's Emerging Infections Program (EIP), 
Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surve illance Network 
(Food Net). In addition to surve illance of resistance in enteric pathogens, the NARMS program at CDC also 
includes public health research into the mechanisms of resistance, education efforts to promote prudent use of 
antimicrobial agents, and studies of resistance in commensal organisms. 
Before NARMS was establ ished, CDC monitored antimicrobial resistance in Sa/monella, Shigella , and 
Campy/obacter through period ic surveys of isolates from a panel of sentinel coun ties . NARMS at CDC began in 
1996 with prospective monitoring of antimicrobial resistance among clinical non-typhoidal Sa/monella and 
Escherichia coli 0 157 isolates in 14 sites. In 1997, testing of clinical Campy/obacter isolates was in itiated in the 
five sites participating in Food Net. Testing of clinica l Salmonefla enterica serotype Typhi and Shigella isolates 
was added in 1999. Since 2003, all 50 states have been forwarding a representative sample of non-typhoida l 
Sa/manella, Salmonella ser. Typh i, Shigella , and E. coli 0 157 isolates to NARMS for antimicrobial susceptibi lity 
testing, and 10 FoodNet states have been participating in Campy/obactersurveillance. Since 2008, ali SO states 
have been forward ing every Sa/monella Paratyphi A and C to NARMS for antimicrobial susceptibil ity testing. 
This annual report includes CDC's surveillance data for 2009 for non-typhoidal Salmonella, typhoidal Salmonella, 
Shigella, Campy/obaeter and E. coli 0157 isolates. Data for earlier years are presented in tables and graphs 
when appropriate . Antimicrobial classes defined by Clinical and Laboratory Standards Institute (CLSI) are used in 
data presentation and analysis. CLSI classes constitute major classifications of antimicrobial agents, e.g ., 
aminoglycosides and cephems. 
This report also includes the World Hea lth Organization's categorization of antim icrobials of critical importance to 
human medicine (Table 1) . The table includes only antimicrobials that are tested in NARMS. 
Additional NARMS data and more information about NARMS activities are available at http://www.cdc.oov/narms 
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WHO Categorization of Antimicrobial Agents 
In 2007, the World Health Organization (WHO) convened for the second time a panel of experts to develop a l ist 
of essential antimicrobial agents according to their importance to human medicine (WHO, 2007). The part icipants 
categorized antimicrobial agents as either Critically Important, Highly Important, or Important based upon two 
criteria: (1) sale therapies or one of the few alternatives to treat serious human diseases and (2) used to treat 
disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms 
ttlat may acquire resistance genes from non-human sources. Antimicrobial agents tested in NARMS have been 
included in the WHO categorization table. 
• Antimicrobial agents are critically important if both criteria (1) and (2) are true. 
• Antimicrobial agents are h ighly important if either criterion (1) or (2) is true. 
• Antimicrobial agents are important if neither criterion is true. 
Table 1. WHO categorization of antimicrobials of critical importance to human medic ine 
WHO 
Category Antimicrobial Agent tested in 




Amoxicill in-clavulanic acid 
Cephems Ceftriaxone 












Highly important Sulfamethoxazole I Sulfisoxazole 







Important Lincosamides Clindamycin 
·In 2010, WHO recategorized tetracycline from high ly important to critically important The NARMS 2010 annual report will renect th is 
change. 
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Summary of NARMS 2009 Surveillance Data 
Population 
In 2009, all 50 states part icipated in NARMS, representing the entire U.S. population of approximately 307 million 
persons (Table 2). Surveillance was conducted in all states for non-typhoidal Salmonella, typhoidal Salmonella, 
Shigella, and EscfJericfJia coli 0157. For Campy/abaeter, surveillance was conducted in 10 sta les that comprise 
the Foodborne Diseases Active Surveillance Network (FoodNet). representing approximately 47 mi11ion persons 
(15% of the U.S. population). 
Clinically Important Antimicrobial Resistance Patterns 
In the United States, f1uoroquinolones (e.g. , ciprofloxacin) and third-generation cephalosporins (e.g ., ceftr iaxone) 
are commonly used to treat severe Salmonella infections, including Salmonella ser. Typhi, the organism that 
causes typhoid fever. In Enterobacteriaceae, resistance to nalidix ic acid , an elementary quinolone, correlates with 
decreased susceptibil ity to c iprofloxacin (MIC ~0. 12 ~g/ml ) and possible f1uoroq uinolone treatment fai lure. A 
substantial proportion of Enterobacteriaceae isolates tested in 2009 demonstrated resistance to these clinically 
important antimicrobial agents. 
Among non-typhoidal Salmonella isolates: 
• 	 1.8% (39/2192) were resistant to nalidixic acid . The most common serotypes among the nalidixic acid­
resistant isolates were Enteritidis (15/39, 38%) and Typhimurium (8/39, 21 %) 
o 	 3.7% (15/410) of Salmonella ser. Enteritidis isolates were nalidix ic acid resistant 
o 	 2.2% (8/371) of Salmonella ser. Typhimurium isolates were nalidixic acid resistant 
• 	 3.4% (75/2192) were resistant to ceftriaxone. The most common serotypes among the ceftriaxone resistant 
isolates were Typhimurium (24/75 , 32%) and Heidelberg (18175, 24%) 
o 	 21% (18/86) of Salmonella ser. Heidelberg isolates were ceftriaxone resistant 
o 	 6.5% (24/371) of Salmonella ser. Typhimurium isolates were ceftriaxone resistant 
Among Salmonella ser. Typh i isolates: 
• 	 60% (217/361) were resistant to nalidixic acid and 3.3% (12136 1) to ciprofloxacin 
Among Shigella isolates: 
• 	 2.1% (10/475) were resistant to nalidixic acid and 0.6% (3/475) to ciprofloxacin 
In Campylobaeter, fluoroqu inolones and macrolides (e.g., erythromycin) are important agents in the treatment of 
severe infections. Among Campy/obacter isolates: 
• 	 23% (344/1502) were ciprofloxacin resistant, including 
o 	 23% (312/1355) of Campylobacter jejuni isolates 
o 	 22% (3111 43) of Campylobaeter coli isolates 
• 	 1.7% (25/1502) were erythromycin resistant, including 
o 	 1.5% (21/ 1355) Campylobaeter jejuni isolates 
o 	 2 .8% (4/143) of Campylobacter coli isolates 
Multidrug Resi stance 
Multidrug resistance is described in NARMS as resistance to three or more ClSI antimicrobial classes. 
Antimicrobial classes of agents defined by the Clinical and l aboratory Standards Institute (elSI) are used in this 
report (Table 3, Table 4). For non-typhoidal Salmonella, an important multidrug-resistant phenotype includes 
resistance to at least ampicill in, chloramphenicol , streptomycin, sulfonamide (sul famethoxazole or sulfisoxazole), 
and tetracycline (ACSSuT). The ACSSuT phenotype includes resistance to at least five ClSI classes. Another 
important phenotype includes resistance to at least ampicillin , ch loramphenicol, streptomycin, sulfonamide, 
tetracycline, amoxicillin-clavulanic acid, and ceftriaxone (ACSSuTAuCx). The ACSSuTAuCx phenotype includes 
resistance to at least 7 ClSI classes. 
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Among non-typhoidal Salmonella isolates: 
• 	 13% (284/2 192) were resistant to two or more CLSI classes of agents, 9.5% (209/2192) to three or more 
CLSI classes. Of the 209 isolates resistant to three or more CLSI classes, 50% were ser.Typhimurium. The 
serotypes with the highest proportion of isolates resistant to three or more CLSI classes were 
o Typhimuri um (28%,104/371), Heidelberg (26%, 22/86), and Newport (7.6%, 18/236) 
• 	 5.1% (1 1212192) were at least ACSSuT resistant. The serotypes with the highest proportion of isolates 
resistant to this phenotype were 
o 	 Typhimuri um (19%,721371) and Newport (6.4%, 15/236) 
• 	 1.4% (30/2192) were at least ACSSuTAuCx resistant. The serotypes with the highest proportion of isolates 
resistant to this phenotype were 
o 	 Newport (6.4%,15/236) and Typhimurium (1.6%, 6/371) 
Add itional isolates resistant to three or more CLSI classes include 
• 	 13% (46/361) of Salmonella ser. Typhi isolates 
• 	 36% (173/475) of Shigella isolates 
• 	 5.9% (11/188) of E. coli 0157 isolates 
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Box 1. Changes in antimicrobial resistance: 2009 vs. 2003-07 
To understand changes in prevalence of antimicrobial resistance over time, we used logistic regression to compare the prevalence of speci fic 
antimicrobial resistance patterns among Salmonella and Campy/abaeter isolates tested in 2009 with the reference, which was the average 
prevalence of res istance in 2003--07. Since 2003, all 50 states have participated in Salmonella surveillance and al110 FoodNel sites in 
Campy/abaeter surveillance. A description of the methods is included in this report (refer to Surveillance and Laboratory Testing Methods). 
The differences between the prevalence of resistance in 2009 and the average prevalence of res istance in 2003-07 (Figure 1) were 
statistically significant for the following" 
Resistance to one or more CLSI classes in non-typhoidal Salmonella (NTS), lower in 2009 (17%) than in 2003--07 (20%) (OR=0.8 , 95% 
CI [0.7-0.9]) 
Resista nce to three or more CLSI classes in NTS, lower in 2009 (9.5%) than in 2003---07 (12%) (OR=0 .8, 95% CI [0.7---0.9]) 
ACSSuTAuCx resistance in Salmonella enterica ser. Newport,lower in 2009 (6A%) than in 2oo3-{)7 (13%) (OR=0.5. 95% CI [0.3-1 .0]) 
Nalidixic acid resistance in Salmonella enterica ser. Typhi , higher in 2009 (60%) than in 2003---07 (49%) (OR=I .6, 95% CI [1 .2-2.0]) 
Ceflriaxone res istance in Salmonella ser. Heidelberg was higher in 2009 (21 %) than the average prevalence of resistance in 2oo3-{)7 (7.9% ) 
(OR=3.5, 95% CI [1.8, 6 .7]) (Figure 1). The data indicate that increased resistance was mainly driven by California and Washington. Trend 
analysis exclud ing Calrtomia and Washington shows no significant change (OR=1A, 95% CI [0 .6, 3.6]). Thus, the reported OR represents a 
summary of unequal trends among sites 
The differences between the prevalence 01 resistance in 2009 and the average prevalence of res istance in 2003-07 (Figure 1) were not 
statistically significant lor the 101l0'Ning' 
Nalidixic acid resistance in NTS (OR=0.9, 95% CI [0.6--1 .2]) 
CeflTiaxone resistance in NTS (OR=I.0, 95% CI [0.8-1 .3]) 
Nalidixic acid resistance in Salmonella enterica ser. Enteritidis (OR=O.7, 95% CI [OA - 1.1]) 
ACSSuT res istance in Salmonella enlerica ser. Typhimurium (OR=0.8, 95% CI [0.6--1.1]) 
Ciprofloxacin resistance in Campylobacter (OR=I .I, 95% CI [1.0-1 .3]) 
Ciprofloxacin resistance in Campylobacter jejuni (OR=1.1 , 95% CI [1 .O-IA]) 
Figure " Summary of trend analysis of the prevalence of specific resistance patterns among Salmonella and Campy/obaeter 
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Antimicrobial Resistance: 1996-2009 

The followi ng figures display resistance from 1996-2009 for non-typhoidal Salmonella, 2000-2009 for Salmonella 
ser. Typhi, and 1997-2009 for Campylobacter. 





Figure 2. Percentage of non-typhoidal Salmonella isolates resistant to ceftriaxone, by year, 1996-2009 
• - Annual percent resistant 
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Figure 5. Percentage of Salmonella ser. Typhimurium isolates resistant to at least ampicillin, 
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Figure 6. Percentage of Salmonella ser. Newport isolates resistant to at least ampicillin, chloramphenicol, 
streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone (ACSSuTAuCx), by 
year, 1996-2009 
. Upper and lower limits of the individual 95% confidence intervals for annual percent resistant 

• - Annual percent resistant 

Figure 7. Percentage of non-typhoidal Salmonella isolates resistant to 1 or more antimicrobial classes, 
by year, 1996-2009 
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Figure 8. Percentage of non-typhoidal Salmonella isolates res istant to 3 or more antimicrobial classes, 
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Figure 9. Percentage of Salmonella ser. Typhi isolates resistant to nalidixic acid, by year , 2000-2009 
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Surveillance and Laboratory Testing Methods 
Surveillance Sites and Isolate Submissions 
In 2009, NARMS conducted nationwide surveillance among approximately 307 million ~ersons (2009 U.S. 
Census Bureau estimates). Public health laboratories systematically selected every 20 non-typhoidal 
Salmonella, Shigella, and Escherichia 00li0157 isolate as well as every Salmonella ser. Typhi , Salmonella 5er. 
Paratyptli A and Safmonefla ser. Paratyplli C isolate received at ttleir laboratories and forwarded these isolates to 
CDC for antimicrobial susceptibility testing. Salmonella ser. Paratyphi B was included in the every 20th sampling 
for non-typhoidal Salmonella because available laboratory methods do not always allow for consistent distinction 
between serotype Paratyphi B (which typically causes typhoidal illness) and serotype Paratyphi B var. 
L(+)tartrate+ (which does not typically cause typhoidal illness). 
Since 2005, public health laboratories of the 10 state health departments that partiCipated in CDC's Foodborne 
Diseases Active Surveillance Network (FoodNet) have forwarded a representative sample of Campy/obaetef 
isolates to CDC for susceptibility testing. The FoodNet sites, representing approximately 47 million persons (2009 
U.S. Census Bureau estimates), include California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New 
Mexico, New York, Oregon, and Tennessee. Depending on the burden of Campy/obacter in each Food Net site, 
one of the following three methods was used to obtain a representative sample of Campy/obacter isolates: all 
isolates received by Georgia , Maryland, New Mexico, Oregon, and Tennessee; every other isolate from 
California, Colorado, Connecticut, and New York; and every fifth isolate from Minnesota. From 1997 to 2004, one 
Campy/obacter isolate was submitted each week from participating FoodNet sites. 
Testing of Salmonella, Shigella, and Escherichia coli 0157 
Antimicrobial Susceptibility Testing 
Sa/manella, Shigella , and E. coli 0157 isolates were tested using broth microdilution (Sensititre®, Trek 
Diagnostics, Cleveland, OH) according to manufacturer's instructions to determine the minimum inhibitory 
concentration (MIC) for each of 15 antimicrobial agents: amikacin, ampicillin , amoxicillin-clavulanic acid , cefoxitin, 
ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin , 
sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table 3). Before 2004, sulfamethoxazole was 
used instead of sulfisoxazole to represent the sulfonamides. Interpretive criteria defined by CLSI were used when 
available. The resistance breakpoint for amikacin , according to CLSI guidelines, is ~64 ~g/mL. In 2002 and 2003, 
a truncated broth microdilution series was used for amikacin testing (0.5-4 ~g/mL). For isolates that grew in all 
amikacin dilutions on the Sensititre panel (MIC>4 ~g/mL), ETest® (AB BIODISK, Solna, Sweden) was performed 
to determine amikacin MIC. The amikacin ETest® strip range of dilutions was 0.016-256 ~g/mL. Since 2004, 
amikacin had a full range of dilutions (0.5-64 ~g/m L) on the Sensititre panel (CMV1AGNF). 
In January 2010, CLSI published revised interpretive criteria for ceftriaxone and Enterobacteriaceae; the revised 
resistance breakpoint for ceftriaxone is MIC ~4 ~g/mL. In this report, NARMS has applied the revised CLSI 
breakpoint for ceftriaxone resistance to data from all years. 
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Table 3. Antimi crobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia 
coli 0157 isolates NARMS 2009 




MIC Interpretive Standard (lJg/mL) 
Susceptible Intermediate Resistant 
Aminoglycosides 
Amikacin 05-& \ <16 32 >64 
Gentamicin 0_25-16 <;4 8 >16 
Kanamycin S-<l4 <16 32 264 
Streptomycin" 32-64 <32 264 
I3-lactam I ~Iactamase 
inhibitor combinations 
Amoxicill in--clavulanic acid 110 _5-32116 ~8/4 16/8 ~3211 6 
Cephems 
Cefoxitin 0.5-32 <8 16 232 
Cefl iofur 0.12---8 <2 • >8 
Ceflriaxonet 0.25-64 <1 2 >4 
Cephalothint 2-32 <8 16 232 
Folate pathway inhibitors 
Sulfamethoxazole§ 16-512 ~256 ~512 
SUlfisoxazole 16-256 ~256 ~512 
Trimethoprim-
sulfamethoxazole 
0.1212.38-4/76 ::;2138 >4176 
Penicillins Ampicillin 1-32 <8 16 232 
Phenicols Chloramphenicol 2-32 <8 16 232 
Quinolones 
Ciproftoxacin 0_015-4 <1 2 2' 
Nalidixic acid 0.5-32 <16 232 
Tetracyclines Tetracycline 4-32 <;4 8 >16 
No CLSI breakpoints; resistance breakpoint used in NARMS is ~64 I-lglmL. 

CLsr updated the ceflriaxone interpretive standards in January, 2010_ Previous standards that were used for NARMS Human 

Isolate reports from 1996-2008 were susceptible ::;8IJglmL, intermed iate 16-32 I-lgfmL, and resistant ~ 1-l9/mL. 

Cephalothin was tested from 1996 to 2003 for Salmonella , Shigella , and E coli 0 157 





Additional Testing of Salmonella Strains 
Cephalosporin Retesting of Isolates from 1996-1998 
Review of Salmonella isolates tested in NARMS during 1996 to 1998 gave conflicting cephalosporin susceptibility 
results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low 
ceftriaxone MIC and, in some cases , did not exhibit an elevated MIC to other (3-lactams. Because these findings 
suggested that some previously reported results were inaccurate, we retested, using the 2003 NARMS Sensititre® 
plate, isolates of Salmonella tested in NARMS during 1996 to 1998 that exhibited an MIC ~2 ~g/mL to cefl iofur or 
ceftriaxone. The retest results have been included in the NARMS annual reports since 2003. 
Serotype Confirmation/Categorization 
Salmonella serotype reported by the submitting laboratory was used for reporting with few exceptions. Serotype 
was confirmed by CDC for isolates that underwent subsequent molecular analysis for publication. Because of 
challenges associated with interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed 
for isolates reported as Salmonella ser. Paratyphi B by the submitting laboratory (serotype Paratyphi B is by 
definition unable to ferment L(+) tartrate). To distinguish Salmonella serotypes Paratyphi Band Paratyphi B var 
L(+) tartrate+ (formerly serotype Java), CDC performed Jordan's tartrate test and/or Kauffmann's tartrate test on 
all Salmonella ser. Paratyphi B isolates from 1996 to 2009 for which the tartrate result was not reported or was 
reported to be negative. Isolates negative for tartrate fermentation by both assays were categorized as serotype 
Paratyphi B. Isolates that were positive for tartrate fermentation by either assay were categorized as serotype 
Paratyphi B var L(+) tartrate+. Confirmation of other biochemical reactions or somatic and flagellar antigens was 
not performed at CDC. 
Because of increased submissions of Salmonella ser. I 4,[5] , 12: i:- noted in previous years, and recognition of the 
possibility that this serotype may have been underreported in previous years, isolates reported as serogroup B 
and tested in NARMS during 1996 to 2009 were reviewed for additional information; isolates that could be clear1y 
identified as serogroup 8 , first-phase flagellar antigen T , second phase flagellar antigen absent were categorized 
in this report as Salmonella ser. 14,[5], 12:i:-. 
Testing of Campy/obaeter 
Changes in Testing Methods in 2005 
Starting in 2005, there were four changes in the methodology used for Campylobaeter. First, a surve illance 
scheme for selecting a representative sample of Campy/abacter isolates for submission by FoodNet sites was 
implemented. State public hea lth laboratories within FoodNet sites receive Campylobaeter isolates from reference 
and clinical laboratories within their state. In 2005, FoodNet sites changed from submitting the first isolate 
received each week to submitting every isolate (Georgia , Maryland, New Mexico, Oregon, and Tennessee), every 
other isolate (California, Colorado, Connecticut, and New York), or every fifth isolate received (Minnesota). The 
number of laboratories submitting isolates ranged from two to aiL Second, the method of species identification 
was updated to para llel what is used by the CDC National Campy/obaeter Laboratory. Third , the susceptibi lity 
testing method changed from Etest® (AB bioMerieux , Solna, Sweden) to broth microdilution. Fourth, there were 
changes in the antimicrobial agents tested. Florfenicol replaced chloramphenicol as the phenicol class 
representative drug, and tel ith romycin was added to the NARMS panel of agents tested. These methods began 
in 2005 and continue through the current year's report. 
Identification/Speciation and Antimicrobial Susceptibility Testing 
From 2005 through 2009, isolates were confirmed as Campy/abaeter by determination of typical morphology and 
motility using dark-field microscopy and a positive oxidase test reaction. Identification of C. jejuni was performed 
using the hippurate hydrolYSiS test. Hippurate-positive isolates were identified as C. jejuni. Hippurate-negative 
isolates were further characterized with polymerase chain reaction (p e R) assays with specific targets for C. jejuni 
(mapA or hipO gene) , C. coli-specific ceuE gene (Linton et al. 1997, Gonzales et al. 1997, Pruckler et a/. 2006), or 
other species specific primers. From 2003 to 2004, putative Campy/abaeter isolates were identi fied as C. jejuni or 
C. coli using BAX® System PCR Assay according to the manufacturer's instructions (DuPont Qual icon, 
Wilmington, DE). Isolates not identified as C. jejuni or C. coli were fu rther characterized by other PCR assays 
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(Linton et al. 1996) or were characterized by the CDC National Campy/obaeter Reference Laboratory. From 1997 
to 2002, methodology similar to that used from 2005 to 2009 was used. 
The methods for susceptibility testing Campy/obaeter and criteria for interpreting the results have changed during 
the course of NARMS surveillance. Beginning in 2005, broth microdilution using the Sensititre® system (Trek 
Diagnostics, Cleveland, OH) was performed according to manufacturer's instructions to determine the MICs for 
nine antimicrobial agents: azithromycin , ciprofloxacin, cl indamycin, erythromycin, florfenicol, gentamicin, nalidixic 
acid, telithromycin, and tetracycline (Table 4). CLSI recommendations for quality control were followed. From 
1997 to 2004, Etest® (AB bioMerieux, Solna, Sweden) was used for susceptibility testing of Campy/obaeter 
isolates. Campylobaeter-specif ic GLSI interpretive criteria were used for erythromycin, ciprofloxacin, and 
tetracycline beginning with the 2004 NARMS annual report. NARMS breakpoints were used when GLSI 
breakpoints were not ava ilable. Beginning in 2004, NARMS breakpoints were established based on the MIG 
distributions of NARMS isolates and the presence of known resistance genes or mutations. In pre-2004 annua l 
reports, NARMS breakpoints used were based on those available for other organisms. Establishment of 
breakpoints based on MIC distributions resulted in higher MIG definitions for azithromycin and erythromycin 
resistance compared withthose reported in pre-2004 annual reports. The breakpoints listed in Table 4 have been 
applied to MIG data collected for all years so that resistance prevalence is comparable over time. 
Table 4. Antimicrobial agents used for susceptibility testing of Campy/abaeter isolates, NARMS, 1997­
2009 
Antimicrobial Agent MIC Interpretive Standard ([Jg/mL)
CLSI class Antimicrobial Agent Concentration Range ([JglmL) 
Susceptible Intermediate Resistant 
Aminoglycosides Gentamicin 0.12-32 <2 4 >80.016-256 
Ketolides Telithromycint 0.015-8 <;4 8 >16 
Lincosamides Clindamycin 
0.03-16 <2 4 >80.016-256 
Azithromycin 0.015-64 <2 4 >8 0.016-256 
Macrolides 0.03-64 Erythromycin 0.016-256 <8 16 >32 
Chloramphenicoli 0.016-256 <8 16 >32 
Phenicols 
Florfenicol§ 0.03-64 <;4 NIA NIA 
Ciprofloxacin 0.015-64 <1 2 >4 0.002-32 
Quinolones 
4-MNalidixic acid 0.016-256 <16 32 >64 
Tetracyclines Tetracycline 0.06-64 <;4 8 >160.016-256 
Etest dilution range used from 1997-2004. 
t Telilhromycin added to NARMS panel in 2005. 
Chloramphenicol, tested from 1997- 2004, was replaced by florfenicol in 2005. 
Currenlly only a susceptible breakpoint (~ I-lg/mL) has been established In this report isolates with a MIC 2":8 Ilg/mL 
are categorized as resistant 
Retesting 
Known mechanisms of quinolone resistance in Campy/obacter are expected to confer equivalent susceptibilities 
to nalidixic acid and ciproHoxacin. Similarly, known mechanisms of macrolide resistance are expected to confer 
equivalent susceptibilities to erythromycin and azithromycin. Confirmatory testing of isolates with conflicting 
results was performed by broth microdilution methods (Sensititre· , Trek Diagnost ics, Cleveland, OH). Tota ls 
reported here reflect the retest resu lts. 
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Data Analysis 
For all pathogens, MICs were categorized as resistant, intermediate (if applicable), or susceptible. Analysis was 
restricted to the first isolate received (per genus under surveillance) per patient in the calendar year. If two or 
more isolates were received for the same patient for Sa/monella ser. Typhi, the first blood isolate collected would 
be included in analysis. If no blood isolates were submitted , tile first isolate collected would be included in 
analysis. Where established, CLSI interpretive criteria were used; streptomycin resistance was defined as MIC 
2:64 ~g/mL (Table 3). The 95% confidence intervals (Cis) for the percentage of resistant isolates are included in 
the MIC distribution tables . The 95% Cis were calculated using the Paulson-Camp-Pratt approximation method. 
When describing results for several years , multidrug resistance for Salmonella, Shigella, and E. eoli 0157 
isolates was limited to the eight CLSI classes (Table 3) tested in all years from 1996 through 2009 represented 
by 15 agents: amikacin, amoxicillin-clavulanic acid, ampicillin, cefoxitin , ceftiofur, ceflriaxone, chloramphenicol , 
ciprofloxacin, gentamicin, kanamycin, nalidixic acid , streptomycin, sulfamethoxazole/sulfisoxazoJe, tetracycline, 
and trimethoprim-sulfamethoxazo le. When describing multidrug resistance for several years for 
Campylobaeter isolates, multidrug resistance was limited to the five CLSI classes tested in all years from 1997 
through 2009, represented by ciprofloxacin, chloramphenicollflorfenicol, clindamycin, erythromycin, nalidixic 
acid, and tetracycline . 
Logistic regression was used to compare the prevalence of antimicrobial resistance among Salmonella and 
Campylobaeter isolates tested in 2009 with the reference, which was the average prevalence of resistance in the 
first five years that NARMS survei llance was nationwide (2003-07). The analysis included the following: 
1. 	 Non-typhoidal Sa/monella: resistance to nalidixic acid, resistance to ceflriaxone, resistance to one or more 
CLSI classes, resistance to three more CLSI classes 
2. 	 Salmonella ser. Enterit idis: resistance to nalidixic acid 
3. 	 Salmonella ser. Typhimurium: resistance to at least ACSSuT (ampicillin, chloramphenicol, streptomycin, 
sulfonamide, and tetracycline) 
4. 	 Salmonella ser. Newport: resistance to at least ACSSuTAuC:x (ACSSuT, amoxicillin-clavulanic acid , and 
ceftriaxone) 
5. 	 Salmonella ser. Typhi: resistance to nalidixic acid 
6. 	 Campy/obaeter species: resistance to ciprofloxacin 
7. 	 Campy/obacter jejuni: resistance to ciprofloxacin 
To account for site-to-site va riation in the prevalence of antimicrobial resistance, we included main effects 
adjustments for site in the analysis. The final regression models for Sa/monella adjusted for the submitting site 
using the nine geographic regions described in the Public Health Laboratory Information System (PHLlS): East 
North Central, East South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic, West North 
Central, and West South Central. For Campy/obacter, the final regression models adjusted for the submitting 
FoodNet site . Odds ratios (DRs) and 95% confidence intervals (C is) were calculated using unconditional 
maximum likelihood estimation. The adequacy of model fit was assessed in several ways . The significance of the 
main effect of year was assessed using the likelihood ratio test. The likelihood ratio test was also used to test for 
significance of interaction between site and year, although the power of the test to detect a single site-specific 
interaction was low. The Hosmer and Lemeshow goodness-of-fit test was also used. Finally, residual ana lysis 
was performed to examine the influence of individual observations. Having assessed that the main effect of year 
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MIC Distr ibution Tables and Proportional Figures 
An explanation on "how to read a squashtogram" has been provided to assist the reader with the different parts of 
each table (Figure 11). A squashtogram shows the distribution of MICs for antimicrobial agents tested. 
Proportional figures visually display data from squashtograms for an immediate comparative summary of 
resistance in specific palhogens and serotypes. These figures are a categorical visual aid for the interpretalion of 
MIC values. For most antimicrobial agents tested, three categories (susceptible, intermediate , and resistant) are 
used to interpret MICs. The proportion representing each category is shown in a horizontal proportional bar chart 
(Figure 12). 
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1. Non-typhoidal Salmonella 
Table 5. Minimum inhibitory concentrations (MICs) and resistance of non-typhoida l Salmonella isolates 
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Figure 13. Antimicrobial resistance pattern for non"typhoidal Salmonella, 2009 




Amoxicili in-clavulanic acid 
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At least ACTtSt 0.9% 
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0.1% , 0.2% 4 0. 1% , 0.1% , 0.1% , 0. 1% 3 0.2% , 0.0% 0 0.2% 4 
Table 6. Percentage and number of non-typhoidal Salmonella isolates resistant to antimicrobial agents , 
-2000 2009 
Year 
Total l liOlates ""1312 ""1410 "",- "" '''' "'" , ~ ""~M ""2113 "" "" "",­ "" ,,~ ~. aSI' Anlimicrobial a., AnIlbiQ1ic (Resistance br\>aI<pOinI ) 
, 
''''V'yCOS' onl "" ,n 
(MIC ~ 64) • • • • • , •,.. • • •Gen!amiein 















(MIC ~ 64) 
16.3'110 
m ,.. 17.1'110 '" 13.2'110 '" 15.0'lI0 '" 12.0'lI0 '" 11.1'110 '" 10.7% '" 10.4'110 m 10.0'lI0 '" .... '"P I3CI"""P bol"",<><e inhbOlor 
combinations 
Arnoxic4l1in el3WIonie 3Cid 







,~.. ,,. " 3.7'110 " 3.3'110 '" 3.1'110 n 3.4'110 "0.00­ -. 
































(MIC ~ 32) 








m... 11 .0'lI0 '" 10.1'110 '" 9.7% n, ... '"...""~ Cipro8oxac;n 
(MIC ~ 4) 
0.4% , .., 0.1% , .., ..• , 0.1% , 0.1% , 0.1% , , 
Nalidixic acid 















2.3%.. ,... " 1.6% "'" 
, 
Aminoglyeo&ides Kanamycin 





















(MIC ~ 32) ' ''' «... 3.4%..... 4.3% " 4.3% " 3.4'10 " ,." 3.5% " ,... " ,... " ' ''' "~hin 






Teste<! ""Tesle<! ""Tesltod ""Te$led ""Te-sled "" TUl e<!...Folate pathway inhibOtcn SullamelhoxazoieiSull soxazoie' 


















'"'" '" Tnn-.ethoprim·sulfamelhoxazole 




















"P!-.enieols "'"""­(MIC ~ 32) 10.' % '" 11. 8%". 8.6'110 '" 10.1'110 '" ,.'" ,.'" 6.4% '" 7.3'110 '" .. '" ,. ~ '"Tetracyclines Telracycline 





















• Rank 01 :>ntimiclllbial, ba$ed on World l-1ea~h Organitation', categontation 01 cn!ical impotlance " tunan ITIIlMne (Table It Rank 1, Critically mpotlant; Rri 2. 11ghIy impotlant 
t CLSI: Clirical and Lat>or<olooy S'...-.:Iard$ In$laule
*Sut1arnelhoxazole, """'cto "'<IS lesled cUing 1>196.2003 te represenl sullonarnides , "'<IS replaced by sull soxazole in 2004. 
Table 7. Resistance patterns of non-tVI hoidal Salmonella isolates, 2000-2009 ,... 
• ClSI: Clinical and laboratory Standards Institute 
t ACSSuT: resis tance to ampicillin. ch loramphenicol. streptomycin. sulfamelhoxazoletsulfisoxazole, tetracycline 
:t: ACTtS: resistance to ampic ill in. chloramphenicol. trimethoprim-sulfamethoxazole 
§ ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clawlanic acid. ceftriaxooe 
33 
Table 8. Twenty most common non-typhoidal Salmonella 











































Paratyphi B var. l (+) tartrate+ 
Hadar 
Poona 
410 (18 .7%) 
371 (16 .9%) 
236 (10.8%) 
105 (4 .8%) 
66 (3.9%) 
72 (3 .3%) 
64 (2 .9%) 
57 (2 .6%) 
56 (2.6%) 
46 (2 .1%) 
44 (2.0%) 
42 (1.9%) 
28 (1 .3%) 
27 (1 .2%) 
21 (1.0%) 
20 (0.9%) 
20 (0 .9%) 
20 (0 .9%) 
19 (0.9%) 
16 (0.7%) 
Subtotal 1760 180.30/. 
Al l other serotypes 
Unknown serotype 
Partial ly serotyped 
RoughlNonmotile isolates 
373 (17 .0%) 
19 10.9%) 
20 (0.9%) 
20 (0 .9%) 
Subtotal 432 119.70/. 








_ _ __ 
•• 
A. Salmonella ser. Enteritidis 
Table 9. Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Enteritidis isolates 
to antimicrobia l agents, 2009 (N=410) _. 
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Figure 14. Antimicrobial resistance panern for Salmonella 5er. Enteritidis, 2009 


























Table 10. Percentage and number of Salmonella seT. Enteritidis isolates resistant to antimicrobial agents, 
-2000 2009 .., ...Vear 






(MIC ~ 64) 
, ~ , ,~ , ,.. ,. ~ , , ~ , ,~ , ,~ , ,~ , ,~ , ,~ , , ~ , Gentamicin 
(MIC ~ 16) 
0.3% , , 0.3% , 0.4% , 0.4% , ,... , ,,. , ,,. , ,.,., ,. ~ , 
Sireptcm)l<: in 
(MIC ~ 64) 
,,. , 1.4% , ,.'", ,,., ,.. ,,. , ,.. ,... , ,,., 0.5%, 0.5%, ,.. ,.,., j!.lactamlj!.lacl,."ase imbler 
combinations 
Am<Olicillj~la\OJlanic acid 
(MIC ~ 32/16) 
,... , ,.. 1.4% , ,'" , , ,.. , 0,8% , 0.5%, 0.5%, ,"" , ~ , ,..'""""', Ceftiolur 
(MIC ~ 6) , ,.. ,,. , ,.. , ,.. , ,.. ,~ , 0.5%, , '" , 0.3'" , ,., ,.. , Ceftna:<<ne 
(MIC ~ 64) , 1.4% , ,
'" 
, ,~ , 0.3% , ,.. 0.5% , 0.3% , , , ~ , ,..Penicilhns Ampicillin 
(MIC ~ 32) '''' " ,.. 6.7'" " ,.. ,." '''', ,.. 4.1'%0 " ",.. 4.4'" " ,.. 2.1'", 3.6'" " " ,..Ouinolone$ Ci~aci n 
(MIC ~ 4) , , ,.. , , ,,., , , ,.,., ,... , , 
Nalidi.ic ac id 
(MIC ~ 32) 





" ,.. '''' " 4.7% " ,... " 5.1% ~ ''"' " ,.. ' ''' " 
" 
ArmnoglYCO$ide$ Kanamyc,n 
(MIC ~ 64) 
0.3'" , ,.. ,'", 0.3'" , , , '" , ,,, , ,,. , 0.5'", , , ,. ,'""""', Cefoxttin 
(MIC ~ 32) , 0.4% , ,.,., ,"", ,"", ''''', 0.5%, 0.3% , ,"", ,~ , 
Ce\lhaIOIhin 
(MIC ~ 32) 
, '" , 1.1 '" , 0.6'" , ,,., "" Tesled '"Tesled '"Te$led '"Tesled '"Tesled No< Tested 
otale pal--" inI"obOlcn Sullamelhox...oteiSull soxazo!e' 
(MIC ~ 512) 
, '" , ,,. , 1.5% , ,,., ,.... , ''"'• 
1.5% , 1.5% , 1.1% , ,.. ..,,, , Tnmelhoprim.. ..ct.me1ho. ...oIe 
(MIC ~ 4176) 
,"", 0.1%, 0.6%, 0.6%, ,"", 0.5'", 0.5%, ' '''', , ,'", ,..PMenicoIs '"""""""'" (MIC ~ 32) ,"", ,,. , ,,, , 0.4% , 0.4'%0 , 0.5%, , "" , ,'", 0.5'" , , 
Tetracyclines Telrac~cljne 
(MIG l 16) 
,.'", 1.6" , , ,. 
" ''"' 
, 3.3'%0, ' ''', 1.7" , ,... " 
1.6'" , ,.,., 
• Ronk of onl imicoOOial$ ba$ed on World I-1eaIlh Orgonilalion"$ caltl9O'ization 01 C<il ical imp:::<tance in ~ medicine (Table I) Rank 1, Cribcally ""pOllan!; Rri 2. Highly knporlarrt 
t CLSI: Ctirical and I.at>or1lle<y Slar>::1ards insl ilute 










Table 12. Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhimurium 
isolates to antimicrobial aaents 2009IN=371) 
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a eSlstance oatterns 0T ble 11 R f SaImane/Iaser. Ententl IS ISO ales 2000 2009-
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• ClSI: Clinical and laboratory Standards Institute 

t ACSSuT: resis tance to ampici ll in. ch loramphenicol . streptomycin. sulfamethoxazole! su lfisoxazole. tetracyc line 

t ACTlS : res istance to ampic ill in. chloramphenicol. trimethoprim-sulfamethoxazole 

§ ACSSuTAuCx: resistance to ACSSuT. amoxicillin-clawlanic acid. ceftri axooe 





Figure 15. Antimicrobial resistance pattern for Salmonella ser. Typhimurium, 2009 

















Table 13. Percentage and number of Salmonella ser. Typhimurium isolates resistant to antimicrobia l 
agents, 2000-2009 
Yea r - ~, ~, ~, - - ­ ~, -Total 19C>lates ~ ~, ~ - ~ ~ - - n,-' aSlt Antimicltlbial Amibiclic O~, lResistance brealcpoim) Amir.ogl~cosides Amikacin 0." 0." 0." 0." 0." 0." 0." 0." 0." 
lMIG ~ 64) 0 0 0 0 0 0 0 0 0 
Gemamicin ,.. ,... ,'" ,'" 2. t 'llo ,... 27'10 2.S'IO ,.. 
(MIG ~ 16) • , , • • • " " •Streptcm)l<: in 39,S% .,... 32.0'M0 35.5% 31 .9% 28 ,1% "" 32,4% 28,5% (MIG l64) "0 "0 ". '" '" m '" '" '"p,.lactaml~tamase irhbitor Amoxicillin·(:I"",lanic acid 6,3% ..,. ,... 5.6% '''' ,,. 4,4% 6.7% 3.3% combinations (MIG ~ 32/16) " " ~ " " " " " ", ""'""" "'"'" 3.6% 3.1% 4.3% ,... 4.4'110 25% ,,. 6.4% 3.3% (MIG ~ 6) " " " " " " " " " Ceflliaxone 3.3% 3.1% ' " ,,. 4.4'110 2S% , ,. 6.4% 3.3% (MIG ~ 64) " " " " " " " " " Penicilhl\S Ampicillin 42,1% 42.5'110 33.8'110 36.3'110 32.1'110 "'" 28,1% 31.7% ",.(MIG ~ 32) '" ". m '" '" '" '" '" ''''""...... Ciprolo. acin 0." 0.3% 0." 0." 0." 0.  ,,. ,... 0." (MIG ~ 4 ) 0 , 0 0 0 0 , 0 0 
Nahdoxic acid L3% 0.6'110 ' " 
,,. 0 .. 0'"' 0.7'110 ,... 1.3'110 
(MIG ~ 32) , , , , , • , • , 
Aminogl~cosides Kanam~cin 13,2% 8.3'110 ,... 7.1% ' ''' S,7'11o S,I '11o ,.. 2.3% (MIG ~ 64) " " ~ " '" " " ,. ,'""""', Ce10xttin ,... 3.1'110 4.3'110 4,4% '''' 2,S'I1o ,... S.7'11o 3.3'110 lMIG ~ 32) " " " " " " " " "Cept>aIoIhin 43'110 3.1'110 5.6'110 6.1% - ~ ~ ~ ~ (MIG ~ 32) " " " " Teste<! Teste<! Tested Te$ted Tested 
" 
Folate pathway irhbitcn SullarnelhoxazoieiSutb e. azoie' 45,4% 43,1'110 32.2% 38.1'110 " "" ~ "" "" 37 ,4'110 "' ,.lMIG ~ 512) '" '" '" ,~ '" 
,., 
'" '" '" nmo)lhoprim'Sulfamelhoxazoie 3,6'110 ,.. 2.3'110 3.4% ,.. ,,, ,,. 2.5'110 1.6% 
(MIG ~ 4116) " 
, , 
" " " 
, 
" 
,-, Ch.... phecot ~... 31 ,1'10 23.4'10 " ,. 24 .3% 24,4%. n ." 25,S%. 23,2% 
(MIG ~ 32) " '" " '" " '" '" '" "Tetracyclines Tet,ac~cline 43,4% 43.4'10 32.0'M0 " ,. 30.3'110 30.4'110 31 ,S'I1o "... 27.S'IO 
(MIG ~ 16) m ,., '" '" '" '" '" '" '" 
-'" 
0." 
















• Rank 01 antimicltlbials based en Wcrk1 Heatth Organization's cat~alion 01 critical impcl'lance in him"" medicine (Table I) Rank 1. Critically Impatant: 1'1..... 2, Highly Impcrtant 
t CLSt Clinica l and Labcratory Slandards Institute
*Sutfamethc>cazole, -.tiel> was tested cUing 110/96.2003 te repre5e<1t sullcnamides, was replaced by sull sexazole in 2004. 
38 
•• •• •• 
•• •• •• 
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C. Salmonella ser. Newport 
Table 15. Minimum inhibitory concentrations (MICs) and res istance of Salmonella ser. Newport isolates 
to ant imicrobial agents 2009 (N=236) 
- %of ......... ""oon' of .. ........ . with .. Ie IPI>'mq-
CLS.t ""'im lero bial c .... ""'imler""... foQ<n. ~ • .• ' $ •• •• 0."$ = •• , , • • .. .. .. ,. $ .,- ,.,". 
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• ClSI: Clini cal and laboratory Standards Institute 
t ACSSuT: res istance to ampic illin. ch loramphenicol. streptomycin. sulfamethoxazole! su lfisoxazole. tetracyc line 

t ACT/S : res istance to ampic ill in . chloramphenicol. trimethoprim-sulfamethoxazole 





• • • • • 
Figure 16. Antimicrobial resistance pattern for Salmonella ser. Newport, 2009 
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(MIC ~ 16) 
2,5% , ,,.• 
3.3% , 3. 1% , 0.'", '", 0.", 0.'" , 0.4% , 0.<1% ,
-Streptomycin 





















































































"Penie illTT\$ Ampicillin 




















""" ­ Ciprolloxac;n (MIC ~ 4 ) 0." 0 0 0. 0 0.0. 0 0.0. 0 0. " 0 0.0. 0 0.0. 0 0.0. 0 0 0. 0 0. " 0 
Nalicb ic acid 
(MIC ~ 32) 
0 ,8% , 0.'" 0 0.8%, 0.4% ,... 0.5'10 , 0.'" 0 0 ,5% , 0.'" 0 0.4% , 0."" 0 
, 
AminoglyCO$ide$ KanamyCin 
(MIC ~ 64) 
,,, , 7.3%• 
10. ~ 
" " ' " 
, ' ''' • 
2,3% , 0.'" , 3.6% , 1. 3% ,
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(MIC ~ 4176) 
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,,., 0.4% , 
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" Tetracyc line. Te tTaGyc hne 
(MIC ~ (6) 
23,1% 

















• RanI< "'anlimicltlbials based on WOIkI Health Organization's categorization '" critical impcrtance in tunan medicine (Table I) RanI< 1. Critically Imponanl ; RanI< 2, Highly Imponant 

t CLSI: Clneal and I..at>:::<1ltooy SI...-.::\a1d$ Instaut, 






Table 18. Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Heidelberg 
isolates to antimicrobial aaents 20091N=861 
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• ClSI: Clini cal and l aboratory Standards Inst itute 

t ACSSuT: res istance to ampic illin. ch loramphenicol. streptomycin. sulfamethoxazole! su lfisoxazole. tetracyc line 

t ACT/S : res istance to ampic ill in . chloramphenicol. trimethoprim-sulfamethoxazole 

§ ACSSuTAuCx: resistance to ACSSuT. amoxic illin-clawlanic acid. cellri axooe 

D. Salmonella ser. Heidelberg 
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Figure 17. Antimicrobial resistance pattern for Salmonella ser. Heidelberg, 2009 

















Table 19. Percentage and number of Salmonella ser. Heidelberg isolates resistant to antimicrobial 
agents,2000-2009 
Yu r - ~, ~, ~, ~ ~. - ~, -Total l90lates n '" ,.. M " ". ", M "-' aSI' Antimicltlbial Amibiclic a~, (Resistance ~aI<pOinl) Am'nogI~cos,des Am,kac,n 0." 0." 0." 0." 0." 0." 0 .. 0." 0." 
(MIC ~ 64) 0 0 0 0 0 0 0 0 0 
Gentamicin ... ,... 3.8% .". 4.3,," 6,4% ... 16,3% 14.1% 
(MIC ~ 16) , • • • • • • " "Streptcm)l<:in n." 25.5% 11.1% 12.5% 1S.2'!Io 13,6% 11,8% 12,2% 30.7% 
(MIC ~ 64) " ~ " " '" H " " "~ach"nlj)-Iac:tamase mbito< Amoxic<lIin-.::I.....lanic acid 3,8% ,.. ... .. . ,.. ... 9,8% 7.1% ... 
combinal ions (MIC ~ 32/16) , , '" • 
, 
" '" 
, • , '"""", ~ 3.S% ,... ,... . .". ." 8,S% 9,S% 1.1% .... 
(MIC ~ 8) , , • • • " '" 
, •
Ceilliallone 3.8% ,.. '''' ..". • N 8,6% ,... 7.1% .... (MIC ~ 64) , , • • • " '" , • Peni<;dlll" Ampicillin 10,1% 9.8% 12.4% 10.4% """ ".. 18,8% 18,4% 26,0% (MIC ~ 32) • '" " '" " " " " "Ouinolones Ciproftoxac:if1 0." 0 .. 0.  0." 0." 0 .. 0." 0." 0." 
(MIC ~ 4) 0 0 0 0 0 0 0 0 0 
l<IaIodoxic acid ,... 0." 0." ,.. 0." ". 0." 0." 0." 
(MIC ~ 32) , 0 0 , 0 , 0 0 0 
AminoglycO$ ides Kanamycin 15,2% 19.6% 10.5% ... '.N 12,8% 6.8% 11.2% 26.7% 
(MIC ~ 64 ) " ro " • • " • " "'"""", Cefoxttin 2,5% ,.. S.6% ..". ,.. ... 8,S% 7.1% .... 
(MIC ~ 32) , , • • , " • , • ~hin 5,1% ,... 10.5% 1.3% - - - - -(MIC ~ 32) • • " , Tested Tested Tested Tested Tested • Folate pathway inhibiteR SullarnelhoxazolelSuI1Iscxazoiet 11,4% 8.S% 6.7% 1.3% ,.. ... ... 18,4% ,2.0% (MIC ~ 512) • • , , , '" • " •Trimelhcprim.sutt.me1 hoxazote 1.3% ,.. ,.. 2.1% 0." 0." 0." 0." 2.1% 
(MIC ~ 4116) , , , , 0 , 0 0 , 
Phenicois a ..... IjlI ... oic:oI 1.3% ,.. ,.. 0." 1.1"" O,S% 0." 3.1% 1.3% 
(MIC ~ 32) , , , 0 , , 0 , , 























• Rank 01 antimic:ltlbiat$ ba$ed en Wcr1d ~~h Organilaticn"$ cattl9O'ilaticn 01 critical imporlanc:e in tunan medicine (Table I) Rank 1. Critically Imporlant; Rri 2, H9>II' Impoolant 
t CLSI: Clinical and Labcratcoy Standards k'l$litule 




E. Salmonella ser. 14,[5],12:i: ­
Table 21 . Min imum inhibitory concentrations (MICs) and resistance of Salmonella ser. 14 ,[5] , 12:i:
isolates to antimicrobial aaents 2009IN=72) 
%ofil..... "",un' 0(" iI"..... ... ~h IUC (J9m Lf 
~. CLSI' Mtim .." I!ioI C"" Mlim Oerolliol-"ll< nt - ,~ ~• .• '5 ,. 0 .12$ ,. , , • • .. .. ,. ~ -•• """" . ' " " '" ""'i>ogly<o.icIo. $1.$ t1 .' "" " u I u I,. ". "' 1 1 - ., " SO-_cOo IB $7,51 ".' ." '" " " ~-Uo;Um I ~-Gct.... ... .....,.-.,-..,,, 
 I ,.." 11.1) ' .2 1,<i<>hib~o< corn lHn....... 
 " " "' " 1 , ,.eepl><m , •• ..-. " I 1 ".', '" eor>-ilx_ w., 1" " "'" , 1.1t1,1 " .$·20.1)""niciI... "' " 1 1" (!p,,­ 100.0auinolo<1o. •• " 1 1" " ., •• ., -~ .... " ' " '" 
...... i>ogly<x>.icIo. 100,0 1-~ " " .,•• " c.....m. eer...., •• ., '.'" " I "" " '".,....... .......... ... milo<. surioox_ 
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Resislar.ce'" 3 CLSI classes ' 7.6% 
• 
7.8% , 12.4% 13 10.4% 10 13.0% 12 15.2% 19 12.7% 13 17.3% 17 28.0% 21 25.6 % 22 


























































































































• ClSI: Clinical and laboratory Standards Institute 

t ACSSuT: resis tance to ampici ll in. ch loramphenicol . streptomycin. sulfamethoxazole! su lfisoxazole. tetracycline 

t ACTlS : res istance to ampic ill in. chloramphenicol. trimethoprim-sulfamethoxazole 






Figure 18. Antimicrobial resistance pattern for Salmonella ser.I 4,[5],12:i :-, 2009 
Antimicrobial Agent Suscepti b le, Intermediate, and Res istant Proportio n 
Amikacin 
Gentamicin 
Streptomycin -• Amoxicillin-clavu lan ic acid 
Ceftiofur 
Ceftriaxone 
Ampicill in -•• Ciprofloxac in 








Table 22. Percentage and number of Salmonella ser.14,[5],12:i:- isolates resistant to antimicrobial 
agents, 2000-2009 
Yu r - ~, ~, ~, - ~, - ~, -Total ISOlates " " » " ~ » >0, n ~...' aSI' Antimicltlbial Amibiclic 
a~, (Resistance ~aI<pOi"") 
Aminogl~cosides Amikacin 0." 0." 0." 0." 0." 0." 0." 0." 0." 
(MIC ~ 64) 0 0 0 0 0 0 0 0 0 
Gentamicin 0." 1.1% 0." 5A,. '''' 0." 4.8% I A,. 3.S" (MIC ~ IS) 0 , 0 , , 0 , , , 
Streptcm)l<:in 1,1% 14.3% ,,. 8.1" '''' ,.. 3.8% ,,. 10.8% (MIC ~ 64) , , , , , , • , , 
~ach"nlj)-Ia(:tamase mbO,or Amoxic<lIin-.::I.,..danic acid 0." 0." ,,. 5.4" ,'" ,... 3,8" 1.4,. 3.S" 
c:ombOnalions (MIC ~ 32/1S) 0 0 , , , , • , , , ",.,.", ~ 0." 1.1" ,,. 5A,. ,.,. ,.. ,..,. 2.1" 3.S" 
(MIC ~ S) 0 , , , , , • , , 
Cellfiuone 0." 0." ,,. 5.4" ,.,. ,... 3.8" 2.1" 3.S" 
(MIC ~ 64) 0 0 , , , , • , , 
Peni<;<lhl\$ Ampicillin 7.1" 7.1" 8.S" 8.1" '''' S,1" 8.1" ,.... 8.4" (MIC ~ 32) , , , , , , , • , 
Ouinolones Ciproftc, ac:if1 0." 0." 0." 0." 0." 0." 0." 0." 0." 
(MIC ~ 4) 0 0 0 0 0 0 0 0 0 
l<IaIidi xic acid 0." 0." 0." ,N ,'" 0." ,.. 1.4" ' .N 
(MIC ~ 32) 0 0 0 , , 0 , , , 
AminoglYCO$ide$ Kanamycin 0." 7.1" 0." 0.,", 0." 0." 0." 1.4" ,,. 
(MIC ~ 64) 0 , 0 0 0 0 0 , , 
""""" CeIox~l n '"' 0.,", 
,,. 5A" ,.,. ''"' ,... 1.4" 3.S" (MIC ~ 32) Tested 0 , , , , • , , 
CepnaIo!hin 0." 1.1% ,,. 5A,. '"' '"' '"' '"' '"'(MIC ~ 32) 0 , , , Tested Tesled Tesled Tested Tested 
• otate palhway mbolOl1o Sullamelhoxazote'Sulisc, azote' 0'"' 14 ,3% 
,,. 5.4% 11.1% 0'"' S,S% 4.1% 13,3% 
(MIC ~ 512) 0 , , , • 0 , , " Trimethcplim·s<M:lme1ho>azote 0'"' 7.1% ,,. 0'"' ,.. 0'"' 0'"' 1.4% 4.S% 
(MIC ~ 4118) 0 , , 0 , 0 0 , • 
Pheniccls a ..............oic:oI 0." 1.1% ,,. 0'"' ,.,. 0." ,... 1.4% ''"'(MIC ~ 32) 0 , , 0 , 0 , , , 





















• Rank ot nimicltlbials based en WCIId Health Organization's cat~za1ien ot c:tilic:al impo:1anc:e in hI.man medicine (Table I) Rank 1. Critically Irnpa1n: 1'1..... 2, Highly Impo:1ant 
t CLSt Clinical and Labcrnlory SIandarc1s instituTe 
; S~hoxazo/.e, ~_ tested 0...;09 1996.2003 to ~t sulblamides,...as replaced by sulfisoxazote in 2004. 
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Table 23. Resistance oatterns of Salmonella ser. 14.rS 12: i:- isolates 2000-2009 
Ye ar 2000 2001 2002 2003 "04 200. 200. 2007 2008 2009 
Tota l Isolates 13 14 35 37 36 33 105 13 83 72 
% % % % % % % % % % 
" " " " " " " " " " No resistal'lCe detected 92.3% 78.6% 91.4% 78.4% 80.6% 87.9% 85.7% 82.2% 77.1% 76.4% 
12 11 32 29 29 29 90 SO 64 55 




















Resis tance ~ 2 ClSI classes" 7.7% 
1 
14.3% , 8.6% 3 10.8% 4 13.9% , 3.0% 1 11 .4% 12 6.8% , 16.9% 14 16.7% 12 






5.4% , 8.3% 3 3.0% 1 9.5% 10 5.5% 4 9.6% • 
12.5% 
9 














2.7% , 7.2% • 
9.7% 
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1.9% , 1.4% 1 3.6% 3 6.9% , 
At least ACTfSt 0.0% 7.1% ' .9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
0 1 1 0 0 0 0 0 0 0 




















At least ceftriaxone and nalidixic acid 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
resistant 0 0 0 0 0 0 0 0 0 0 
• ClSI: Clini cal and laboratory Standards Institute 
t ACSSuT: resis tance to ampici ll in. ch loramphenicol . streptomycin. sulfamethoxazole! sulfisoxazole. tetracyc line 
t ACTlS : res istance to ampic ill in. chloramphenicol. trimethoprim-sulfamethoxazole 
§ ACSSuTAuCx: resistance to ACSSuT. amoxicillin-clawlanic acid. ceftri axooe 
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F. Specific Drug Resistance Phenotypes 
Table 24. Number and percentage of isolates with resistance to at least ACSSuT, ACSSuTAuCx, nalidixic 
acid. and ceftriaxone among the 20 most common non-typhoidal Salmonella serotypes iso lated in 
NARMS 2009 









1 Enteritidis 410 0 (0.0%) 0 (0.0%) 15 (38.50/0) 0 (0_0%) 
2 Typhimurium 371 72 (64 .3°/~ 6 (20.0%) 8 (2 0.50/0) 24 (32.00/~ 
3 Newport 236 15 ( 13.4°/~ 15 (50 .0%~ 0 (0.0%) 15 (20.0"/~ 
4 Javiana 105 0 (0 .0%) 0 (0.0%) 1 (2.6%) 1 (1.3%1 
5 Heidelberg 86 3 (2.70/~ 1 (3 .3%) 0 (0.0%) 18 (24.0%) 
6 14.[5].12:i:­ 72 5 (4 .50/~ 0 (0 .0%) 0 (0.0%) 2 (2.7%) 
7 Oranienburg 64 0 (0 .0'%) 0 (0.0%) 0 (0 .0%) 0 (0.0%) 
8 Saintpaul 57 1 (0 .9%1 0 (0 .0%) 1 (2.6%) 0 (0 .0%) 
9 ~ntevideo 56 0 (0.0%) 0 (0 .0%) 0 (0.0%) 0 (0_0%,) 
10 Braenderup 55 0 (0.0%) 0 (0 .0%) 0 (0.0%) 0 (0_0%) 
11 Infantis 44 2 (1.8%1 2 (6.7%) 1 (2.6%) 5 (6 .7%) 
12 M-lenchen 42 0 (0 .0%) 0 (0 .0%) 0 (0.0%) 0 (0 .0%) 
13 Mssiss ippi 28 1 (0 .9%1 0 (0 .0%) 0 (0.0%) 0 (0.0%) 
14 Thompson 27 0 (0 .0%) 0 (0.0%) 0 (0 .0%) 0 (0.0%) 
15 .JI9ona 21 2 ( 1 .80/~ 2 (6 .7%) 1 (2 .6%) 2 (2.7%) 
16 Bareilly 20 0 (0.0%) 0 (0 .0%) 0 (0.0%) 0 (0_0%) 
17 Litchfield 20 0 (0 .0%) 0 (0 .0%) 0 (0.0%) 0 (0.0%) 
18 Paratyphi B var. L(+) tartrate+ 20 2 (1.8%1 0 (0 .0%) 0 (0.0%) 1 (1.3%) 
1. Hadar ,. 0 (0.0%) 0 (0 .0%) 1 (2 .6%) 0 (0_0%) 
20 Poona 16 0 (0.0%) 0 (0 .0%) 0 (0.0%) 0 (0_0%) 
Subtotal 1769 103 (92.0%) 26 (86 .7~kI 28 (71 .8%~ 68 (90.7I'.Q 
All oth er serotypes 364 5 (4 .5%) 3 (10 .0%) 8 (20.5%) 6 (8.0%) 
Unknown serotype ,. 1 (0.9%) 1 (3.3%) 2 (5. 1%) 1 (1.3%) 
Pa rtially serotyped 20 2 (1.8%) 0 (0.0%) 1 (2.6%) 0 (0_0%) 
RoughlNonmotile isolates 20 1 (0 .9%) 0 (0.0%) 0 (0 .0%) 0 (0.0%) 
Total 2192 112 (100.00/"­ 30 (100 . 0~ 3. (100.0°/0) 75 (100.0%1 
• ACSSuT: at least resistant to ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline 




• • • • 
• • • 
Box 2. Four major multidrug-resistant patterns among non-typhoidal Salmonel/a 
isolates, 1996-2009 
During 1996-2009, 3,243 (13.0%) of 24,903 non-typhoidal Salmonella isolates tested in NARMS were resistant to 
2:3 classes of antimicrobial agents. Among the 3,243 isolates, we identified the 4 most common multidrug­
resistant (MDR) patterns based on resistance to 7 of the 15 agents currently tested in NARMS: ampicillin (A). 
chloramphenicol (C), streptomycin (8 ). sulfonamide (Su). tetracycl ine (T), amoxicillin-clavulan ic acid (Au), and 
ceftriaxone (ex). Unlike MDR criteria used for tables in the rest of this report, which defined "at least ACSSuT" as 
resistant to at least A, C, S, Su, and T, we used mutually exclusive criteria in this section: ACSSuT was defined 
as resistant to A, C, S, Su, and T, not resistant to Au and Cx; ACSSuTAuCx as resistant to all 7 agents; ASSuT 
as resistant to A, S, Su, and T, not resistant to C, Au, and Cx; and SSuT as resistant to S, Su, and T, not resistant 
to A, C, Au, and Cx. Use of mutually exclusive criteria is important in monitoring major and emerging patterns, 
which may be driven by different resistance mechanisms. 
ACSSuT, ACSSuTAuCx, ASSuT, and SSuT isolates accounted for 73.1% of the 3,243 isolates resistant to 2:3 
classes: 1,323 (40.8%) were ACSSuT , 476 (14.7%) ACSSuTAuCx, 295 (9.1%) ASSUT, and 275 (8.5%) SSuT. 
Serotype Typhimurium accounted for 90.0% of ACSSuT and 74.6% of ASSuT isolates. Of the ACSSuTAuCx 
isolates, 67.0% were serotype Newport and 19.8% were serotype Typhimurium. More than half of SSuT isolates 
were serotypes Typh imurium (26.6%), Stanley (12.7%), Derby (10.2%), and Heidelberg (9.8%). 
Figure 1 below shows the percentage of the 4 MDR patterns by year among all non-typhoidal Salmonella isolates 
tested from 1996 through 2009. ACSSuT declined from 8.2% in 1996 to 3.7% in 2009. ACSSuTAuCx, first 
detected in 1997, peaked at 3.4% in 2002 before declining to 1.4% in 2009. ASSuT was :53.0% and SSuT was 
s1 .7% from 1996 through 2009. 
Refer to Table 7 in the Results section of 1his report for the percentage of "at least ACSSur by year (2000-09) 
among non-typhoidal Salmonella isolates, which includes ACSSuT and ACSSuTAuCx. Since "at least 
ACSSuTAuCX" in Table 7 includes resistance to all 7 agents , percentages are the same as in F igure 1. 
Figure 1 . Percentage of 4 major MDR patterns· among non-typhoidal Salmonella is olates, 
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"Four most commo n mu lt id rug ....es istant MDR) pa tterns t hat include resi stance to ~3 ant imicrobial classes and 
any of t he fo llowi ng agents: ampicill in (A), ch lo ramphenicol (C), streptomycin (S), sulfonamide (Su), 










2. Typhoidal Salmonella 
A. Salmonella ser. Typhi 
Table 25. Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhi isolates to 
antimicrobial agents, 2009 (N=361) 
- % of .. ...... ""OOn' <If .. .." .....w ~h .. Ie !PI>'m l.r Cl.st' Antim ...0 .... C I. .. Antim ...""... Ao;I<nt ,>, O .Oj~ o.us .~ N•• •• •• • • • " " " •• '",... """.•• ., no ,H ........ .......-..... , ­ ." •• I I 
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Figure 19. Antimicrobial resistance pattern for Salmonella ser. Typhi , 2009 
Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
Amikacin 















Table 26. Percentage and number of Salmonella ser. Typhi isolates resistant to antimicrobial agents, 
-2000 2009 
Year 
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• Rank 01 anlimicltltlials based on World Heallh Clfganization's cat~alion 01 crili~ impalance On ......"" medcOne (Table I) Rank 1, Crilicall~ I"nponant: Rank 2. HighI~ Irn,oor1anI. 

t CLSI : OirWeal and Laboralory SIandardf, In$mute 

t SlMamethoxazoie• ...nell was teste<! during 1996-2003 to represent sutlor\arnides, was repla.eed by sUlhoxa:zote in 2OCl4. 

Table 27. Resistance patterns of Salmonella ser. Tvphi isolates, 2000-2009 
Year 
















































































































































































12.9% ., 18.6% 60 15.2% 61 12.2% 50 10.5% 38 










































• ClSI: Clinical and laboratory Standards Institute 
t ACSSuT: resistance to ampicillin. ch loramphenicol . streptomycin. sulfamethoxazole! sulfisoxazole. tetracyc line 
t ACT/S : resistance to ampic ill in. chloramphenicol . trimethoprim-sulfamethoxazole 
§ ACSSuTAuCx: res istance to ACSSuT. amoxici llin-clawlanic acid. celtriaxone 
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Figure 20. Antimicrobial resistance pattern for Salmonella ser. Paratyphi A, Paratyphi B, and Paratyphi C, 
2009 



























Table 29. Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Paratyphi A, 
Paratyphi B and Paratyphi C isolates to antimicrobial agents 2009 (N=102) 
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B. Salmonella ser. Paratyphi A, Paratyphi B, and Paratyphi C 







Paratyphi A 100 (98.0%) 
Paratyphi B 1 (1 .0%) 
Paratyphi C 1 (1 .0%) 
Total 102 (100.0%) 
Table 30. Percentage and number of Salmonella ser. Paratyphi A , Paratyphi S, and Paratyphi C isolates 
resistant to antimicrobial agents, 2000-2009 
Year 
Total l9C>lates _. "" , "" , "" '" "" • "'" " "" " "" " ""H "" " "" '" aSI' Antimicrobial 
a • • 
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Table 31. Resistance patterns of Salmonella ser. Paratyphi A, Paratyphi S, and Paratyphi C isolates, 
2000 2009 -
Year 
TOla llsolates ""5 2001 9 2002 10 '''' • '''' 11 
2005 


























" No resistar.ce dete<:ted 40.0% , 44.4% 4 "'.0%, 12.5% 1 27.3% 3 33.3% 6 50.0% 8 5.9% 1 12.0% 11 12.7% 13 
Resistance ~ 1 CLSI class" 60.0% 
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• CLSI: Clinical and Laboratory Standards Inst itute 
t ACSSuT: resistance to ampicillin, chloramphenicol , streptomycin, sulfamethoxazolefsulfisoxazole, tetracyc line 
:I: ACTIS : resistance to ampicillin . chloramphenicol . trimethoprim-sulfamethoxazole 
§ ACSSuTAuCx: resistance to ACSSuT. amoxicillin-clawlanic acid. cellriaxone 
S1 
Box 3. Molecular characterization of Non-Typhi Salmonella enterica that show 
decreased susceptibility to extended-spectrum cephalosporins 
Although most Salmonella infections are self-l imited and treated symptomatically, antimicrobial therapy is 
necessary for the management of invasive infections. The recommended regimen used to include either 
amoxicili in or trimethoprim-sulphamethoxazole, but due to increased resistance levels to these drugs, cu rrent 
recommendations suggest using a fluoroquinolone, such as ciprofloxacin, or an extended-spectrum 
cephalosporin, such as cefiriaxone. 
Among 4,236 isolates of non-typhi Salmonella (NTS) submitted to NARMS in 2005 and 2006, 175 (4.1 %) 
displayed decreased susceptibility (MIC 2: 2 mg/L) to the extended-spectrum cephalosporins cefiriaxone or 
ceftiofur. Among these, thirty diffe rent serotypes were represented and the three most prevalent serotypes were 
Newport (33. 1%), Typhimurium (13.7%) and Heidelberg (13. 1%). 
Among the 175 isolates, 172 were ava ilable for molecular analys is. For each isolate, genomic DNA was prepared 
and the presence of ~-Iactamase genes investigated by polymerase chain reaction (PCR) amplification targeting 
six different genes: blaTEM. blaOXA. blasHv. blaCTX.M.blapSE and blaCMY. 
One or more ~-Iactamase genes were detected in 139 (60.6%) isolates. The most prevalent resistance 
mechanisms were AmpC f3-lactamase genes (blaCMY) which were identified in 133 (95.7%) of the 139~­
lactamase-carrying isolates. The ceftriaxone MIC-values for the blacMv-containing isolates ranged from 4 to 64 
mg/L; all blaCMy-bearing isolates were thereby classified as ceftriaxone resistant according to current CLSI 
guidelines. 
Other ~-Iactamase genes detected included eleven blaTEM.l . three blapSE.l, two blaOXA.l and one blaCTX.M.15.The 
latter is an extended-spectrum ~-Iactamase (ESBL) that exhibits increased activity against cefotaxime and confers 
cross-resistance to the fourth generation cepha losporin cefepime. The blaCTX.M.15 gene was found in an isolate of 
serotype Concord and is the second CTX-M-producing Salmonella identified in the NARMS human isolate 
coliection (the first case was a CTX-M-S-producing Salmonella ser. Typhimurium isolated from a 3-month old ch ild 
in 2003). The source of the CTX-M-1S-producing Salmonella remains unknown, but it is likely that the infection 
was acquired abroad since the patient reported international travel to Ethiopia in conjunction with illness onset. 
In conclusion, among NTS isolated from humans in 2005-2006, CMY p-Iactamases were the predominant cause 
of decreased susceptibil ity and resistance to extended-spectrum cephalosporins. To limit further spread of these 
genes, prudent use of antimicrobial agents in both human and veterinary medicine will be crucial. Continued 
surveillance for cephalosporin-resistant bacteria among humans remains critical . 
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Box 4. Reduced azithromycin susceptibility in Shigella sonnei, United States 
Shigella spp. are a major cause of gastroenteritis in the United States, transmitted most commonly by the fecal­
oral route. It occurs most o ften in children 5 years old and younger in child care settings. While treatment with 
antimicrobial agents may shorten the duration of clinical symptoms for this usually self-limiting disease, 
emergence of antimicrobial resistance has recently made drug selection difficult. Previous drugs of choice for 
treatment of shigellosis were ampicillin and trimethoprim-sulfamethox8zole, but resistance to these drugs is high, 
especially in Shigella sonnei. Because of resistance to these agents, the macrolide azithromycin has been 
recommended by the American Academy of Pediatrics for treatment of shigellosis in children. Azithromycin 
resistance in Shigella sonnei is now being reported, but there are currently no ClSI criteria for interpretation of 
azithromycin susceptibility test results for Shigella. To explore azithromycin susceptibility in the United States, we 
determined MIC distributions for Shigella sonnei isolated from humans in the United States. 
Azithromycin MICs were determined by broth microdilution for Shigella sonnei isolates from 11 recognized 
outbreaks in 10 states in 2006-2007 (n=56) and for those submitted routinely to NARMS in 2005 (the most 
recently completed year at the time, n=336) from 44 states. Five isolates collected from 1969-1974 (before 
approval of azithromycin) were also tested for historical perspective, but were not included in the MIC distribution 
analysis. Each isolate that demonstrated an azithromycin MIC>64 mg/L was screened for the mphA gene by 
PCR, and the gene was sequenced to confirm positives. 
The resulting distribution was log-normal and spanned three doubling dilution steps (4-16 mg/L) with an MICso 
and MICoo of 8 mg/L. Five isolates collected from 1969-1974 exhibited azithromycin MICs of either 4 m9/L (n=1) 
or 8 mg/L (n=4) . One outbreak iso late and two routine isolates showed MICs at least four-fold higher than the 
MICoo for the overall group of isolates; the outbreak isolate displayed an MIC of 256 mg/L and the routine isolates 
showed MICs of 256 and 128 mg/L. These isolates were PCR-positive for mphA, which encodes a macrolide-2'­
phosphotransferase. In all three isolates, the gene was on a transferrable plasmid, with plasmid sizes ranging 
from 15-150kb. 
Decreased azithromycin susceptibility for Shigella sonnei in the face of high levels of ampicill in and trimethoprim­
sulfamethoxazole resistance is particularly worrisome for children because the remaining options for treatment 
are ceftriaxone, which is administered by injection and fluoroquinolones such as ciprofloxacin, wh ich are not 
approved for use in children. Continued surveillance will be needed to examine antimicrobial use practices for 
Shigella infections and to determine whether azithromycin use leads to decreased susceptibil ity to the agent. 





Table 33. Minimum inhibitory concentrations (MICs) and res istance of Shigella isolates to antimicrobial 
agents 2009 (N=475) 
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Figure 21. Antimicrobial resistance pattern for Shigella, 2009 
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Table 34. Percentaae and number of Shiaella isolates resistant to antimicrobial aaents 2000-2009... 
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• ClSI: Clini cal and laboratory Standards Institute 

t ACSSuT: resis tance to ampici ll in. ch loramphenicol. streptomycin. sulfumethoxazolelsulfisoxazole. tetracycline 

t ACTiS : res istance to ampic ill in . chloramphenicol. trimethoprim-sulfumethoxazole 

§ ATI S: res istance to ampicill in. trimethoprim-sulfumethoxazole 

11 ANTiS : resistance to ATiS . naladixic acid 

•• ACSSuTAuCx: res istance to ACSSuT. amoxicillin-clawlanic acid. ceftriaxone 
Table 36. Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents 2009 (N=410) 
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Figure 22. Antimicrobial resistance pattern for Shigella sonnei, 2009 
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• ClSI: Clin ical and laboratory Standards Institute 

t ACSSuT: resistance to ampicillin. chloramphenicol. streptomycin. sulfamethoxazolelsulfisoxazoie. tetracycline 

i ACT/S: resistance to ampicillin. chloramphenicol. trimethoprim-sulfamethoxazoie 

§ ATtS: resistance to ampici llin. trimethoprim-sulfamethoxazole 

11 ANTI S: resistance to ATI S. naladixic acid 

•• ACSSuTAuCx: ",,,i,,tancll !o ACSSuT. amoxieillin--cla;ulanic acid. cllftriaxonll 
Table 39. Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
aaents 2009 (N=57) 
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Table 38. Resistance patterns of Shigella sonnei isolates, 2000-2009 
Year 

























































































































































































































































































Figure 23. Antimicrobial resistance pattern for Shigella flexneri, 2009 
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• Rank "'lIntim iCfd)ials t..ased on World Health OIQanilati(ln's categorization '" critical impotlance in tunan n-.edicine (Table I) Rank 1. Critically Impotl...; Ran< 2, ~ Impotl... 

t ClSI: Clirical and i..oIl>or1ltOty Slandan;k Instaute 

t $L.itlilmen>o. ",,~e,...tVcn was tested duing 1996-200310 ~ent $<Monamides. was ~aced by sL.i' soxal:oIe in 2004 . 
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Table 41. Resistance patterns of Shigella f1exneri isolates, 2000-2009 
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• ClSI: Clinical and laboratory Standards Institute 
t ACSSuT: resistance to ampicillin. chloramphenicol. streptomycin . sulfamethoxazolelsulfisoxazole. tet racycline 
i ACT/S: resistance to ampicillin . chloramphenicol. tri methoprim-sulfamethoxazole 
§ ATtS: resistance to a mpici llin. trimethoprim-sulfamelhoxazole 
11 ANTIS: resistance to ATIS . naladixic acid 
•• ACSSuTAuCx: ",,,i,,tanc ll !o ACSSuT. amoxiei llin--cla;ulanic acid . cllllriaXOniO 
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Figure 24. Antimicrobial resistance pattern for Escherichia coli 0157, 2009 



































4. Escherichia coli 0157 
Table 42. Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli 0157 isolates to 
antimicrobial agents, 2009 (N=168) 
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• Rank cf iIIlIIITlICrobiiD based go Work! Health Q'ginzallClll·SCategoozatlClll cf cnlic;alllllPOflance In tunan mediCine (T~e I) Rank 1. Crilic;ally mpor\<W1I: Rank 2, ttgtIy mpor\<W11 
t CLSI: O inical and Labcratory Standards nsl~ute 
t Sullarnelhox~oIe. ....ch ""'" lesle<! <b'ng 199&-2003 to represent $~. ""'" ,eplace<! by $oJ!i$OX~oIe in 2004. 
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2.1% , 2.5%, 5.9% 11 
Resistance;!: 4 CLSI classes ' 3.4% 
14 
1.4% , 08% J 1.3% 2 0.6% , 10% 2 2 1% 5 1.1% 2 1.3% 2 43% 8 
Resistance;!: 5 ClSI classes ' 1.2% , 0.4% , '''', 0.0% , 0.0% , 00% , ,,% , 0.5% , 0.0% , 05% , 
At least ACSSuV 1.2% , 0.4% , 0.0% , 0.0% , 0.0% , 0_0% , ,,% 2 0.0% , 0.0% , '<l% 0 
At least ACT/SI 0.2% , 0.0% 0 0.0% 0 0.0% , 0.0% 0 0_0% 0 0.0% , 0.0% , 0.6% , 0.0% 0 
At I.."~t ACSSuTAuCx t 1.0% , 0.4% , 0.0% , 0.0% , 0.0% 0 0.0% 0 '<l% , 0.0% , 0.0% 0 ' .0% 0 












0,4%, 0.0% 0 0.0% 0 ' .0% 0 
• ClSI: Clinical and Laboratory Standards Institute 
t ACSSuT: resistance to ampicillin. chloramphenicol. streptomycin. sullamettloxazoleJsullisoxazoie. tetracycline 
:t: ACT/S: resistance to ampicil lin. chloramphenicol, trimettloptim·su lfamettloxazole 





Table 46. Minimum inhibition concentrations (MICs) and resistance of Campy/abaeter isolates to 
antimicrobial agents 2009 (N=1502J _. Pe«ont 01 •• ;lOlol.. w~~ "' IC II'tIm L)"'1. 01 iso"'" 
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Figure 25. Antimicrobial resistance pattern for Campy/obaeter, 2009 
Antimicrobial 
Agent Susceptible, Intermediate, and Resistant Proportion 
5. Campy/abaeter 
a 45 Frequenc~ 0 Ieampylo acfer species isolated in NARMS, 2009T ble I b 
Species 2009 
N (0/01 
Campy/obaeterjejuni 1355 (90.2%) 
Campylob acterco/i 14 3 (9.S%) 
OIhe, 4 (0 .3%) 
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T•ble 47 Percentage and nurnber 0 Ie I bampylo acter ISO ates resistant to antlmlcrob·,.I agents, 2000-2009 
" Rank ",_moert)/lill/$ t>aSed onW<)I\d _h Qrvanilation'$ c~l<I\IOIIl:l'J!K)n "'Cnli~ ""pOrt/InCe", run"".-e;.... (TO/JIel): _ I. CrI1icIllIy mporlMl; R_ 2. HigNy mporlotll ~.... 3. m PQl1an1 
t CLSt Cliniclll and L~bor!lIory SI_ Ins I~Ule 
t Only. s uscep!iCle _poinI (S. ~~)1Ies beenesloblshed. irllM repoIi . isolates ";Ih 11\ MIC . 8 ~ml are categorized as reslslotll 
Table 48. Resistance patterns of Camoviobacter isolates 2000-2009 
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Tobllsolates """". "''' '" """. "'" '" "'" '" ""." "" '" "" "00 
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" No resistance detected 52.2% 
16' 
49.2% ,., 48.3% 171 50.9% 167 46.1% '60 48.4% 431 43.9% 358 45.2% 497 45.8% '" 
46.4% 
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" CLSI Clinical and Laboratory Standards Institute 
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Table 49. Minimum inhibitory concentrations (MICs) and resistance of Campy/obacter jejuni isolates to 
antimicrobial agents 2009 (N=1355) _. 
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Figure 26. Antimicrobia l resistance pattern for Campy/obacter jejuni, 2009 
Antimicrobial 

















Table 51. Minimum inhibitory concentrations (MICs) and resistance of Campy/obacter coli isolates to 
antimicrobial agents 2009 (N=143) _. "',unl 01 11 .. ........ h .. 1C I,.,..,L)­% 01 .. 0",'.. 
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1 Q.$I (5'Ii< ...... l .....-,. _ ....._ 
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rt OnIy .....op<*Oo~(• • ~ ..... _ .._heoi hhsfepot\.iI_. " .... IItC.s~ .... .~.... '..io..... 
- - - - -Table 50. Percentage and number of Campy/obaeterjejuni isolates resistant to antimicrobia l agents, 2000-2009 ru , TOIII))ooIol," * ~, ~ -,,n ~, ~ m ~. n, ." ~, ~ ,­ ,~ 
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t CLS): Clinical and Lobc<a!oty Stanclarcls 1n$1~Ule 




Table 52. Percentage and number of Campy/obaeter coli isolates resistant to antimicrobial agents, 2000­
_. ~, ~,v.., ~. ~..To. IIO<>I.... n M ~ .0 2009 - - - - -". "" " " " ClS~ AnlimierQ/lilll l~nu(>iOlie 
~ jRes;slanCe _po;nI) 
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~... 47.1'" 12.Q'Ifo 22.7'110 ~ ,.. 23.~ 21 .6'Ifo 28.6'110 ~ " ... 21.7%~, l~clO"'Cin , , 
 , ,(MIC ~ 4) n ~ ~ 
47.1'110 12.Q'Ifo 23.1%2V'IIo ~,5'" 30.5'110n"." "I;:a'idi.>:ie acid ~.'" ~'""."", , , , ,(MIC ~ 64) ~ ~ ~ 
p_ot. ~ "~ ~ ~..'"..'" ..'" ..'" ..'"l;;-pI>onicoI
(MIC ~ 32) Tesle<l Tested Te-ste<l Teste<l Tuted• • • • • ... " ...~ ~ ~ ~ ~ ..'"..'" .. ~ '" I~~• S...ceptible _pcUM ,""'Ie S 4) Tnted Tnted T....ted Tested Tesled • • • • • 
40,1NTetracyclines ~ ,.. ~... 45.~ ~... ~.N 41.9'Ifo 4.4.8%M."I~elracyc."" ~.'" (MIC ~ 16) ~ ~ ~ ~ ~ ,".. "... , 2,1 %Lincosamkln 8.3'110 "9.1"'­ 4.1"'­ 9.1"'­9.3'" '.N•.. "'" I~YCin , , ,• (MIC ~ 8) ••• • " 
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t CLSt CIri;8I and LaborlItory Stonclard$ Io$trtute 
t Only" suscep!ible _point j5 419ml) 11M been ntablished. In this report. isolates with "" Mle ~ 8\9..,. .... categorized as res;stant 
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INTRODUCTION 
Escherichia coli is a Gram-negative coccobacillus bacterium that is part of the intestinal flora of humans and 
other animals. Because antimicrobial resistance genes commonly reside in mobile genetic elements that can be 
transferred horizontally to other bacteria, antimicrobial-resistant bacteria of the intestinal flora, includ ing E. coli, 
constitute an important reservoir of resistance genes for pathogenic bacteria of humans and other anima ls. 
Furthermore, when introduced into a normally sterile site, E. coli is an important cause of infections, including 
septicemia, urinary tract infections, and wound infections. The human intestinal tract is the predominant source of 
E. coli causing these infect ions. Antimicrobial resistance among E. coli causing such infections compl icates 
treatment options. 
The use of antimicrobial agents creates a selective pressure for the emergence and dissemination of resistant 
bacteria. Use of antimicrobial agents in food animals selects resistant bacteria, including resistant E. coli in the 
intestinal tract of food animals. These resistant bacteria can be transmitted to humans through the food supply. 
Therefore, monitoring resistance in E. coli isolated from the intestinal flora of humans and animals is important to 
determining the role of these bacteria as human pathogens and as reservoirs of resistance determinants for 
human pathogens. The E. coli Resistance Surveillance Pilot is designed to determine the prevalence of 
resistance to clinically important antimicrobial agents among E. coli isolated from persons in the community. 
SUMMARY OF 2009 SURVEILLANCE DATA 
Background 
Beginning in 2004, NARMS began to prospectively monitor the prevalence of antimicrobial resistance of E. coli 
isolated from human stool samples in two sites: Maryland and Michigan. 
SURVEILLANCE AND LABORATORY TESTING METHODS 
In 2009, Michigan was the sale participant in the study. Michigan cultured 10 human stool samples, from 
outpatients, each month for E. coli using Eosin Methylene Blue agar and subsequent biochemical confirmation. 
One E. coli isolate, if present, from each stool sample was sent to CDC for susceptibility testing to antimicrobial 
agents using broth microd ilution (Sensititre®) to determine the minimum inhibitory concentration (MIG) for each of 
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15 antimicrobial agents: amikacin, ampici ll in, amoxiciliin-clavulanic acid, cefoxitin , ceftiofur, ceftriaxone, 
chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfonamides, tetracycline, 
and trimethoprim-sulfamethoxazole. 
Interpretive criteria from the Clinical and Laboratory Standards Institiute (CLSI) were used when available (Table 
53). The 95% Cis for the percentage of resistant isolates calculated using the Clopper-Pearson exact method, are 
included in the MIC distribution tables. Similarly, multiclass resistance by CLSI antimicrobial class was defined as 
resistance to two or more classes. 
RESULTS 
In 2009, CDC received 45 isolates; of these, 45 (100.0%) were viable E. coli isolates. MIC was determined for E. 
coli isolates for 15 antimicrobial agents (Table 54). Of the 45 E. cofi isolates, 22.2% (10/45) were resistant to 
ampicill in, 17.8% (8/45) to sulfisoxazole, 17.8% (8/45) to tetracycline, and 8.9% (4/45) to nalidixic acid (Table 55 ). 
Multidrug-Resistant E. coli 
Multidrug resistance is described in NARMS by the number of antimicrobial classes and also by specific 
coresistant phenotypes. Antimicrobial classes of agents defined by CLSI are used in this report. 
• 	 11.1% (5/45) of E. coli isolates were resistant to three or more classes of antimicrobial agents (Table 56 ). 
• 	 8.9% (4/45) of E. coli isolates were resistant to five or more classes of antimicrobial agents (Table 56). 
Clinically Important Resistance 
Antimicrobial agents commonly used to treat serious E. cofi infections in humans include third-generation 
cephalosporins and fluoroquinolones. 
• 	 2.2% (1/45) of E. coli isolates were resistant to ceftriaxone (Table 55). 
• 	 8.9% (4/45) of E. coli isolates were resistant to ciprofloxacin (Table 55). 
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Table 54. Minimum inhibition concentrations (MICs) and resistance of Escherichia coli isolates to 
antimicrobial agents 2009 (N=45 
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·bT fE h . h ·T bl 53 Antlm lcrob·••I aaents usedfor susceotl I ltv testma 0 sc eric la corI 2009• e 
Cl S Iclass Ant imicrobial Agent Ant imicrobia l Agent MIC Interpretive Standard (lJg/rnl) 
Concentration Susceptible Int ermediate Res is t ant 
Ra nge (lJg/rn L) 
Aminogl}COsides Amikacin 05 64 m 32 "4 
Gentamicin 0.25 16 " 
, ' 16 
Kanam~in 8 64 m 32 "4 
Streptomycin 32 - 64 S32 "4, lactam 1j3· lactamase inh ibi tor 
combinations Amoxic iliin-Cla'A.llanic acid 1/0 .5-32116 :!is/4 16/8 ~32/16 
Cephems Cefoxitin 0.5 32 " 16 '32 Cefliofur 0.12 , ' 2 4 "Ceftriaxone 0.25 64 " 2 >4 Folate pathway inhibilors Sulfisoxazole 16 - 256 ,.;:256 <':512 
Trimethoprim Sulfamethoxazole 0.1212.4 - 4176 ,.;:2f3 8 <,:4176 
Pen icill ins Ampicillin 1 32 " 16 >32 Phen icols Chloramphenicol 2 32 ,. 16 >32 
Quinotones Ciproftoxacin 0.015 4 " 2 >4 Nalidixicacid 0.5 - 32 ' 16 '32 




Figure 28. Antibiotic resistan ce pattern for Escherichia coli, 2009 
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Folate pathway inhibitors Sultiso~azole: 




















































• Rank 01 antimicrobials b-ased 00 World Health Organizatioo's categorizatioo of critical importance in human medicine (Table I): Rank 1. 
Critically Important: Rank 2. Highly mportant 
t ClSI: Cl inical and laboratory Standards Institute *Result s unawilable fOr 5 isolates 
73 
T bl 56a e ReSlstance oatterns 0 f E h " h " sc eric ,a co I ISO ates 2004-2009 
Year 2004 2005 2006 2007 2008 2009 
Total Isolates 151 11. .2 66 57 45 
% % % % % % 
" " " " " " No res istance detected 62 .9% 63.0% 63.4% 65.2% 64 .9% 68.9% 
95 75 52 43 37 31 
Resistance :!: 1CLSI class · 37 .7% 37.0% 36 .6% 34 .8% 35.1 % 3U % 
57 44 30 23 20 1. 
Resistance;:O:2 CLSr classes ' 17.9% 22 .7% 22 .0% 21.2 % 21 .1% 13.3% 
27 27 1. 1. 12 6 
Resistance:;:"3 CLSI classes' 9 .9% 14 .3% 15.9% 15.2% 12.3% 11.1% 
15 17 13 10 7 5 
Resistance 2:4 CLSI classes ' 



















5 9 1 3 • • 
N. least ACSSurt 1.3% 0.8% 0 .0% 0.0% 1.8% 0.0% 
2 1 0 0 1 0 
N. leastACT/St 1.3% 0.8% 1.2% 1.5% 3.5% 0.0% 
2 1 1 1 2 0 
At least ACSSuTAuCx§ 0.0% 0.0% 0 .0% 0.0% 0 .0% 0.0% 
0 0 0 0 0 0 
At least ceflriaxone and nalidixic acid resistant 0.0% 0.0% 0 .0% 0.0% 1.8% 2.2% 
0 0 0 0 1 1 
• CLSI : C lin ical and Laboratory Standards Institute 

t ACSSuT : res istance 10 ampicillin , chloramphenicol , streplom}'t: in, sulfamethoxazole/su lfisoxazole, 

letrac~l i ne 
:j: ACT/S : resistance 10 ampicill in, chloramphenicol, trimethoprim -sul famethoxa2D le 
§ ACSSuT.A.uClC res istance to ACSSuT, amoxicill in-ciawlanic acid , ceftriaxone 
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